學門類別
政大
哈佛
最新個案
- Leadership Imperatives in an AI World
- Vodafone Idea Merger - Unpacking IS Integration Strategies
- Snapchat’s Dilemma: Growth or Financial Sustainability
- V21 Landmarks Pvt. Ltd: Scaling Newer Heights in Real Estate Entrepreneurship
- Predicting the Future Impacts of AI: McLuhan’s Tetrad Framework
- Did I Just Cross the Line and Harass a Colleague?
- TNT Assignment: Financial Ratio Code Cracker
- Porsche Drive (A): Vehicle Subscription Strategy
- Porsche Drive (A) and (B): Student Spreadsheet
- Porsche Drive (B): Vehicle Subscription Strategy
-
Health View Bioanalytic Limited: Generating Impact from Research
Benny Chung-Ying Zee was a professor at a prestigious university in Hong Kong and founder of Health View Bioanalytic Limited (Health View). Health View offered fast, inexpensive, non-invasive assessments of the risk of stroke and Alzheimer’s disease by using artificial intelligence and automatic retinal image analysis (ARIA) of pictures of patients’ retinas using fundus cameras. While Health View was breaking even, Zee realized that it was not yet a success. Thus, Zee was considering how to scale up the company to realize the impact of its technology. Zee had to assess the current business model—its value proposition, target market, sales channels, and strategic partners—and determine how he could scale up and redirect Health View. -
Bamboos Health Care Holdings (Hong Kong) Ltd.: Business Model and Expansion
The chief executive officer of Bamboos Health Care Holdings (Hong Kong) Ltd. (Bamboos) started her entrepreneurship journey in 2005 with a telephone and a fax machine. She created a platform to match the demand from patients or their relatives with the supply of services from health care professionals. After 12 years in operation, following one consistent business model, Bamboos was listed on the main board of the Hong Kong Stock Exchange. Despite several challenges in its early years, the Bamboos business model proved to be sustainable in Hong Kong and became resistant to change. In early 2018, the founder was considering entering the health care market in mainland China and changing the company’s business model for the first time. Could the current business model in Hong Kong be modified to enter mainland China and other countries? What changes would be required with respect to strategy and management?